OPKO Health Inc (OPK) Stock AnalysisOPKOPKO Health Inc

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

OPKO Health Inc. is a good buy right now due to its current price of $1.63, a recent RSI of 62.50 indicating bullish momentum, and a significant increase in hedge fund buying activity of 1498.79% over the last quarter. However, the main risk is the projected EPS of -0.07 for the next earnings date on November 4, 2026, which could lead to volatility.

6 analysts cover OPK: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 2.75.